Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences reported Q1 2026 financial results, ending the period with $14.1 million in cash, which management believes is sufficient to fund operations into the first quarter of 2027. The company announced a key regulatory milestone, reaching an agreement with the FDA on a single adaptive Phase 2/3 study for the approval of Gemini in treating acute kidney injury.
Key figures
- Guidance
- fund operations through the first quarter of 2027
- Net loss
- 3009051
- Rd expense
- 1376861
- Cash position
- 14113415
- Warrant proceeds
- 6700000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.